Savsu to supply Novartis’ newly-approved SMA treatment

By Vassia Barba

- Last updated on GMT

(Image: Getty/ClaireMcAdams
(Image: Getty/ClaireMcAdams

Related tags: Novartis, Savsu Technologies, AveXis, Zolgensma

Novartis to continue with AveXis’ adoption of Savsu’s evo cold chain management technology for newly-approved gene therapy.

Savsu Technologies, a New Mexico, US-based company, which creates temperature controlled systems and transport containers developed the evo Cold Chain 2.0 system especially for cell and gene therapies shipments.

Evo ‘smart shippers’ of the Cold Chain 2.0 system were designed to offer thermal stability and to have integrated sensor and communication systems. The containers are connected with evo.is, a cold chain cloud application providing real-time data whilst in transit.

The technology was adopted by AveXis, the developer of Zolgensma (onasemnogene abeparvovec-xioi), which is the first one-time gene therapy for the treatment of spinal muscular atrophy (SMA) in children less than two years old.

Novartis acquired AveXis​ in April 2018 for $8.7bn (€7.79bn) and led Zolgensma to receive approval​ from the US Food and Drug Administration (FDA) last month.

Currently, 44% of Savsu’s shares are owned by Biolife Solutions, which also has an exclusive option to purchase all remaining shares.

Mike Rice, CEO of BioLife, commented on the partnership with Savsu, saying that the company looks forward to additional announcements related to new Savsu customers.

Related news

Show more

Related products

show more

Microaerobic Fermentation of Lactobacillus acidophilus

Microaerobic Fermentation of Lactobacillus acidophilus

Eppendorf for Bioprocess – Solutions that grow with you | 01-Oct-2019 | Application Note

We successfully performed microaerobic fermenta¬tion of a probiotic strain, Lactobacillus acidophilus, at a very low oxygen level, representing the natural...

Removing Aggregates of an Acidic Monoclonal Antibody

Removing Aggregates of an Acidic Monoclonal Antibody

Bio-Rad Laboratories | 22-Oct-2018 | Technical / White Paper

CHT Ceramic Hydroxyapatite Media/Resins are known as the industry gold standard for
impurity removal during monoclonal antibody (mAb) purification....

Single-Step Influenza and Dengue Virus Purification

Single-Step Influenza and Dengue Virus Purification

Bio-Rad Laboratories | 08-Oct-2018 | Application Note

CHT XT is the newest addition to the CHT family of media. It has been designed for superior physical robustness to ensure it can be used repeatedly over...

Related suppliers

Follow us

Products

View more

Webinars